CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-02 | Balcom Alexandra Director | Grant or award · Stock Option (Right to Buy) | +11,050 | 11,050 | ||
| 2026-06-02 | Moran Susan Director | Grant or award · Stock Option (Right to Buy) | +11,050 | 11,050 | ||
| 2026-06-02 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +11,050 | 11,050 | ||
| 2025-12-15 | Pinkas Jan Chief Scientific Officer | Grant or award | +17,507 | 17,507 | ||
| 2025-12-15 | Pinkas Jan Chief Scientific Officer | Grant or award | +5,000 | 22,507 | ||
| 2025-12-15 | Pinkas Jan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +70,025 | 70,025 | ||
| 2025-12-15 | Doughty Christopher Grant Chief Business Officer | Grant or award | +14,714 | 54,194 | ||
| 2025-12-15 | Doughty Christopher Grant Chief Business Officer | Grant or award | +8,000 | 62,194 | ||
| 2025-12-15 | Doughty Christopher Grant Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +58,855 | 58,855 | ||
| 2025-12-15 | Brumm Joshua T Chief Executive Officer | Grant or award | +45,117 | 313,517 | ||
| 2025-12-15 | Brumm Joshua T Chief Executive Officer | Grant or award | +10,000 | 323,517 | ||
| 2025-12-15 | Brumm Joshua T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +180,467 | 180,467 | ||
| 2025-12-15 | Scalzo Richard William Chief Financial Officer | Grant or award | +14,422 | 14,422 | ||
| 2025-12-15 | Scalzo Richard William Chief Financial Officer | Grant or award | +5,000 | 19,422 | ||
| 2025-12-15 | Scalzo Richard William Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +57,688 | 57,688 | ||
| 2025-12-15 | McNeill Jonathan President and COO | Grant or award | +19,507 | 153,707 | ||
| 2025-12-15 | McNeill Jonathan President and COO | Grant or award | +6,000 | 159,707 | ||
| 2025-12-15 | McNeill Jonathan President and COO | Grant or award · Stock Option (Right to Buy) | +78,029 | 78,029 | ||
| 2025-12-15 | Im Ellie Eunkyung Chief Medical Officer | Grant or award | +16,298 | 16,298 | ||
| 2025-12-15 | Im Ellie Eunkyung Chief Medical Officer | Grant or award | +5,000 | 21,298 |
Page 2 of 16 · 305 trades